DataString Consulting Company Logo
DataString Consulting Company Logo
Automated And Closed Cell Therapy Processing Systems Market
Home»Recent Reports»Automated And Closed Cell Therapy Processing Systems Market

Automated And Closed Cell Therapy Processing Systems Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1801063, Published - January 2025

Segmented in Product Type (Automated Cell Therapy Processing), End User (Hospitals, Clinics), Application, Technology and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Automated And Closed Cell Therapy Processing Systems
Market Outlook

Automated and Closed Cell Therapy Processing Systems are crucial in reshaping the field of technology today. The market, for Automated and closed cell therapy processing systems was estimated at $1.5 billion in 2024. It is anticipated to increase to $4.6 billion by 2030 with projections indicating a growth to around $11.8 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 20.8% over the forecast period. Their groundbreaking feature lies in their ability to streamline cell production processes. As health challenges continue to drive the need, for sophisticated and reliable cell therapy treatments worldwide; these automated systems lead the way by offering an innovative solution that can greatly enhance quality of life and push forward current healthcare standards.


Expanding on the concepts of safety and efficiency while emphasizing repeatability aspects well Automated and Closed Cell Therapy Processing Systems assist in validating, isolating and handling human cells for medical applications. Their distinctive closed system layout reduces the chances of contamination creating a working environment, for human cell processing activities.


Market Size Forecast & Key Insights

2019
$1.5B2024
2029
$9.8B2034

Absolute Growth Opportunity = $8.3B

The Automated And Closed Cell Therapy Processing Systems market is projected to grow from $1.5 billion in 2024 to $9.8 billion in 2034. This represents a CAGR of 20.8%, reflecting rising demand across Automated Collection and Separation of Cells, Autologous and Allogenic Therapies and Product Standardization.

The Automated And Closed Cell Therapy Processing Systems market is set to add $8.3 billion between 2024 and 2034, with industry players targeting Cardiovascular Diseases & Orthopedic Conditions Application projected to gain a larger market share.

With Rising prevalence of chronic diseases, and Technological innovations in cell therapy, Automated And Closed Cell Therapy Processing Systems market to expand 562% between 2024 and 2034.

Opportunities in the Automated And Closed Cell Therapy Processing Systems Market

Advancing Personalized Medicine

The growing popularity of medicine is leading to a higher need for customized treatment options, in the medical field.

Expanding into Regenerative Medicine and Pediatric Therapies

With increasing pharmaceutical interest in regenerative medicine,There'sa substantial growth opportunity for Automated and Closed Cell Therapy Processing Systems. These systems can provide effective solutions for the mass-production of stem cells and other regenerative therapies, which are becoming increasingly critical in treating a range of degenerative diseases. Innovative applications within human body repair, including tissue engineering and organ replacement, are still relatively untapped markets in many regions.

Currently cell therapy processing systems are mostly focusedon treating adult diseases; however it is increasingly acknowledged that these treatments could be highly beneficial for conditions as well. Especially those stemming from genetic factors or where existing treatments fall short in effectiveness. Unlocks the potential of this approach could lead to an advancement, in theindustry'sprogress.

Growth Opportunities in North America and Europe

Europe Outlook

The European market is rapidly growing due to advancements in healthcare and a growing number of patients seeking treatment options face tough competition but the rise in demand for effective cell therapy systems presents promising opportunities for growth businesses must navigate regulatory hurdles by focusing on compliance to stay ahead, in the market.

North America Outlook

The American market for Automated and Closed Cell Therapy Processing Systems is fiercely competitive and well established because of leading companies in the field and advancements in healthcare infrastructure. With a rise in investments in cell therapy research and increased awareness of the advantages these technologies offer alongside legal regulations fostering their use. It creates ample room, for market expansion opportunities.

North America Outlook

The American market for Automated and Closed Cell Therapy Processing Systems is fiercely competitive and well established because of leading companies in the field and advancements in healthcare infrastructure. With a rise in investments in cell therapy research and increased awareness of the advantages these technologies offer alongside legal regulations fostering their use. It creates ample room, for market expansion opportunities.

Europe Outlook

The European market is rapidly growing due to advancements in healthcare and a growing number of patients seeking treatment options face tough competition but the rise in demand for effective cell therapy systems presents promising opportunities for growth businesses must navigate regulatory hurdles by focusing on compliance to stay ahead, in the market.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, China, Japan, United Kingdom are expected to grow at 20.0% to 29.1% CAGR

2

Emerging Markets : Brazil, India, South Africa are expected to grow at 15.6% to 21.6% CAGR

Market Analysis Chart

The field of cell therapy processing has undergone changes due to advancements in technology that have introduced Automated and Closed Cell Therapy Processing Systems into the market with wide acceptance and integration. Various factors influence this market environment as catalysts for progress and obstacles hindering it. One significant driving factor is the increasing need, for therapeutic solutions to combat chronic illnesses like cancer, heart diseases and autoimmune disorders.

Recent Developments and Technological Advancement

November 2024

Life Science Innovations has introduced the CT 1000. An automated closed system, for cell therapy processing that boasts superior efficiency.

August 2024

Gen Tech BioPharma launched the G CelPro system—a cutting edge automated cell therapy processor—expanding their range of offerings, in the market.

April 2024

StemCell Tech introduced their product called AdvanceCell 24. This cutting edge automated system offers a range of choices, in the field of cell therapy as it operates in a closed environment.

The advancements in the market for Automated and Closed Cell Therapy Processing Systems have been notable and forward looking.One prominent trend in this sector is the increasing favor towards automated systems that remove the requirement for involvement to reduce the risk of contamination and errors while ensuring consistency. This shift, towards automation is enhancing the effectiveness of cell therapies. Facilitating substantial scalability.

Impact of Industry Transitions on the Automated And Closed Cell Therapy Processing Systems Market

As a core segment of the Medical Device industry, the Automated And Closed Cell Therapy Processing Systems market develops in line with broader industry shifts. Over recent years, transitions such as Shift Towards Automation and Upswing in Closed Cell Therapy Processing Systems have redefined priorities across the Medical Device sector, influencing how the Automated And Closed Cell Therapy Processing Systems market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Shift Towards Automation:

The field of cell therapy processing systems is undergoing a transition towards automation as a response, to the intricate nature and strict regulatory standards linked with cell therapy manufacturing; automated systems are now playing a vital role in the production process by enhancing effectiveness and maintaining regulatory adherence while minimizing costly errors that could impact the cell therapy sector significantly. Major pharmaceutical firms are dedicating resources to automated cell therapy processing systems to enhance their production lines and guarantee accuracy and consistency. This strategic move is fuelled by the goal of boosting market expansion.

2

Upswing in Closed Cell Therapy Processing Systems:

The industry is witnessing an increase, in the utilization of closed cell therapy processing systems.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Medical Device industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Medical Device industry cascade into the Automated And Closed Cell Therapy Processing Systems market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rising Prevalence of Chronic Diseases, and Increasing Investment in Regenerative Medicine

The rising prevalence of long term illnesses like diabetes and cancer is also fueling the need for more efficient treatment solutions in the healthcare industry. Automated and Closed Cell Therapy Processing Systems offer an adaptable method for treatment that aligns well with the increasing demand, for such tailored care options.
The field of medicine is also experiencing significant growth and is also attracting considerable funding from various sources. Both public and private alike. Automated and Closed Cell Therapy Processing Systems play a role in this field and are also directly benefiting from the rise, in financial backing.
Technological progress in the realm of cell therapy is also driving the demand for Automated and Closed Cell Therapy Processing Systems forward. Impressive developments, in gene modification methods and cell culture approaches are also enhancing the efficiency and availability of these systems.

Restraint: High Costs Involved

One major challenge encountered in the Automated and Closed Cell Therapy Processing Systems industry is the considerable expenses linked to the technologys implementation and upkeep expenses like system procurement and maintenance costs may pose a strain, for healthcare facilities that need to stay current with technological advancements through frequent upgrades and replacements.

Challenge: Regulatory Constraints

Regulatory restrictions in regions pose a significant obstacle to the markets expansion by causing delays in approvals and hindering the effective implementation and use of the system. Compliance, with standards set by healthcare regulatory agencies may result in delays and increased expenses while also stalling progress and hindering market growth.

Supply Chain Landscape

R&D & Conceptualization

Thermo Fisher Scientific

Miltenyi Biotec

Material & Component Procurement

Sartorius AG

Becton Dickinson

Manufacturing & Assembly
Lonza Group / GEM Group
Distribution & End-user Application
Takara Bio / Asahi Kasei Medical
R&D & Conceptualization

Thermo Fisher Scientific

Miltenyi Biotec

Material & Component Procurement

Sartorius AG

Becton Dickinson

Manufacturing & Assembly

Lonza Group

GEM Group

Distribution & End-user Application

Takara Bio

Asahi Kasei Medical

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeadingProvidersProvider Strategies
Cell-based Immunotherapy
Biotechnology
Miltenyi Biotec
Innovation and development of integrated solutions for cellular therapy
Regenerative Medicine
Healthcare
Thermo Fisher Scientific
Expanding scientific research to improve patient care
Drug Discovery and Development
Pharmaceuticals
Beckman Coulter
Collaboration with leading pharmaceutical companies for high-quality therapeutic cell development
Stem Cell Research
Life Sciences
GE Life Sciences
Focus on advanced stem cell technologies and application-specific tools

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Automated And Closed Cell Therapy Processing Systems market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Automated And Closed Cell Therapy Processing Systems in Autologous and Allogenic Therapies, Product Standardization and Automated Collection and Separation of Cells

Autologous and Allogenic Therapies

These advanced systems are widely used in donor cell therapies for treating conditions such as cancer by modifying patient specific cells to enhance treatment effectiveness and minimize contamination risks for better cell purity standards in therapy processes Companies like Thermo Fisher Scientific and GE Healthcare lead the way, in driving this field forward

Product Standardization

Automating the processing of cell therapy also helps in maintaining product quality and ensuring outcomes in various batches used in medical environments. This technology ensures consistency between batches of products. Meets the demands for producing on a large scale while reducing processing time significantly. This trend hints towards a move towards available cell therapies which is becoming popular among key companies, like Sartorius and Stemcell Technologies.

Automated Collection and Separation of Cells

Automated systems for cell therapy processing speed up. Improve the process of collecting and isolating cells effectively and accurately. These systems are capable of separating cells with great precision and dependability which is a significant benefit for their use in precision medicine and regenerative therapies. Key companies in the market, like Miltenyi Biotec and Terumo BCT are making use of these systems to offer high quality cell therapies.

Automated And Closed Cell Therapy Processing Systems
vs. Substitutes: Performance and Positioning Analysis

Automated and Closed Cell Therapy Processing Systems offer increased productivity and sterility compared to manual alternatives. With the rising demand for cell therapies, these technologies position themselves uniquely for significant market growth.

Automated And Closed Cell Therapy Processing Systems
  • Open System Cell Processing /
  • Outsourced Cell Therapy Services
    High efficiency, minimization of contamination risks
    High initial setup costs, requirement of specialized training
    High efficiency, lower risk of contamination
    High equipment costs, requires specialized training

Automated And Closed Cell Therapy Processing Systems
vs. Substitutes: Performance and Positioning Analysis

Automated And Closed Cell Therapy Processing Systems

  • High efficiency, minimization of contamination risks
  • High initial setup costs, requirement of specialized training

Open System Cell Processing / Outsourced Cell Therapy Services

  • High efficiency, lower risk of contamination
  • High equipment costs, requires specialized training

Automated and Closed Cell Therapy Processing Systems offer increased productivity and sterility compared to manual alternatives. With the rising demand for cell therapies, these technologies position themselves uniquely for significant market growth.

Loading...

Research Methodology

This market research methodology defines the Automated And Closed Cell Therapy Processing Systems market scope, gathers reliable data, and validates findings through integrated primary and secondary research. Our systematic framework ensures precise market sizing, adoption analysis, and competitive benchmarking tailored to solution-driven ecosystems.


Secondary Research Approach


We initiate secondary research by defining the targeted market at both Regional and Country levels. As part of the Medical Device ecosystem, we analyze Automated And Closed Cell Therapy Processing Systems across Hospitals and Clinics Applications. Data is systematically gathered from country level ministerial sources, industry associations & federations, company annual & quarterly reports and other credential sources, allowing us to map solution deployment trends, pricing models, compliance requirements, and technology adoption pathways.


Key Sources Referenced:


We benchmark competitors such as GE Healthcare, Lonza Group AG, and Thermo Fisher Scientific Inc. using verified industry reports, customer case studies, company disclosures, and partner ecosystem strategies. Our secondary insights uncover solution-specific drivers and inhibitors, which form the foundation for targeted primary research.


Primary Research Methods


We conduct structured interviews and surveys with solution stakeholders, including R&D & Conceptualization, Material & Component Procurement, and Manufacturing & Assembly. Geographic coverage spans North America (45%), Europe (33%), and Asia-Pacific (22%) and Middle East & Africa (5%). Our online surveys generally achieve a 72% response rate, while expert interviews deliver an 86% engagement level, resulting in a 93% confidence level with ±6.1% margin of error.


Through targeted questionnaires and in-depth interviews, we capture adoption motivators, integration challenges, return-on-investment perceptions, and solution stickiness across enterprise segments. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering and Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Adoption-Rate modeling to forecast solution demand with precision.


Top-down and Bottom-up Process


In the Top-down approach, we disaggregate global Medical Device revenues to estimate the Automated And Closed Cell Therapy Processing Systems segment, leveraging enterprise digitalization budgets and IT spending patterns. In the Bottom-up approach, we aggregate deployment data at the country and vertical levels, considering subscription volumes, integration projects, and solution renewals to forecast regional and global adoption. By reconciling both approaches, we ensure statistical robustness and forecast reliability.


We further map the solution delivery value chain spanning R&D & Conceptualization (Thermo Fisher Scientific, Miltenyi Biotec), Material & Component Procurement (Sartorius AG, Becton Dickinson), and Manufacturing & Assembly. Our parallel substitute analysis examines Open System Cell Processing and Outsourced Cell Therapy Services, highlighting diversification opportunities and competitive risks.


Company Market Share and Benchmarking


We benchmark leading solution providers such as GE Healthcare, Lonza Group AG, and Thermo Fisher Scientific Inc., analyzing their strengths in deployment scalability, integration capabilities, customer retention, and partner ecosystem development. Company revenues, case deployments, and recurring revenue streams are assessed to estimate market shares and clarify competitive positioning.


Our integration of triangulated data, ecosystem mapping, and solution benchmarking, enhanced by our proprietary Directional Superposition methodology, ensures precise forecasts and actionable strategic insights into the Automated And Closed Cell Therapy Processing Systems market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Automated And Closed Cell Therapy Processing Systems Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 1.8 billion
Revenue Forecast in 2034USD 9.8 billion
Growth RateCAGR of 20.8% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 20241.5 billion
Growth OpportunityUSD 8.3 billion
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD billion and Industry Statistics
Market Size 20241.5 billion USD
Market Size 20272.6 billion USD
Market Size 20293.8 billion USD
Market Size 20304.6 billion USD
Market Size 20349.8 billion USD
Market Size 203511.8 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredProduct Type, End User, Application, Technology
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledGE Healthcare, Lonza Group AG, Thermo Fisher Scientific Inc., Miltenyi Biotec, Stemcell Technologies Inc., Terumo BCT, Merck KGaA, Novartis AG, PlasmaGen BioSciences, STREX Inc., Corning Incorporated and Medipost
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Automated And Closed Cell Therapy Processing Systems Market Size, Opportunities & Strategic Insights, by Product Type

4.1Automated Cell Therapy Processing
Chapter 5

Automated And Closed Cell Therapy Processing Systems Market Size, Opportunities & Strategic Insights, by End User

5.1Hospitals
5.2Clinics
Chapter 6

Automated And Closed Cell Therapy Processing Systems Market Size, Opportunities & Strategic Insights, by Application

6.1Oncology
6.2Cardiovascular Diseases
6.3Orthopedic Conditions
6.4Wound Healing
Chapter 7

Automated And Closed Cell Therapy Processing Systems Market Size, Opportunities & Strategic Insights, by Technology

7.1Stem Cell Therapy
7.2CAR-T Cell Therapy
7.3T-Cell Receptor Therapy
7.4Tumor-Infiltrating Lymphocytes-Based
Chapter 8

Automated And Closed Cell Therapy Processing Systems Market, by Region

8.1North America Automated And Closed Cell Therapy Processing Systems Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Automated And Closed Cell Therapy Processing Systems Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Automated And Closed Cell Therapy Processing Systems Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Automated And Closed Cell Therapy Processing Systems Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Automated And Closed Cell Therapy Processing Systems Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Automated And Closed Cell Therapy Processing Systems Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1GE Healthcare
9.2.2Lonza Group AG
9.2.3Thermo Fisher Scientific Inc.
9.2.4Miltenyi Biotec
9.2.5Stemcell Technologies Inc.
9.2.6Terumo BCT
9.2.7Merck KGaA
9.2.8Novartis AG
9.2.9PlasmaGen BioSciences
9.2.10STREX Inc.
9.2.11Corning Incorporated
9.2.12Medipost